Regeneron Pharmaceuticals, Inc.
MX ˙ BMV ˙ US75886F1075
SecurityMX:REGN / Regeneron Pharmaceuticals, Inc.
InstitutionEpoch Investment Partners, Inc.
Latest Disclosed Ownership238,725 shares
Latest Disclosed Value $ 184,448,484
Epoch Investment Partners, Inc. reports 15.15% decrease in ownership of REGN / Regeneron Pharmaceuticals, Inc.

On May 14, 2026 - Epoch Investment Partners, Inc. filed a 13F-HR form disclosing ownership of 238,725 shares of Regeneron Pharmaceuticals, Inc. (MX:REGN) valued at $184,448,484 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 281,335 shares of Regeneron Pharmaceuticals, Inc.. This represents a change in shares of -15.15% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 238,725 -42,610 -15.15 184,448 -15.06 0.5782
2026-02-13 2025-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 281,335 22,182 8.56 217,154 49.03 1.2339
2025-11-13 2025-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 259,153 56,096 27.63 145,714 36.69 0.8006
2025-08-13 2025-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 203,057 -4,399 -2.12 106,605 -18.98 0.5515
2025-05-14 2025-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 207,456 10,190 5.17 131,575 -6.37 0.6824
2025-02-13 2024-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 197,266 39,526 25.06 140,518 -15.26 0.6809
2024-11-13 2024-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 157,740 -5,556 -3.40 165,823 -3.38 0.7427
2024-08-13 2024-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 163,296 59,745 57.70 171,629 72.20 0.7837
2024-05-14 2024-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 103,551 103,551 99,667 0.4431
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.